Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia.

Weng XQ, Shen Y, Sheng Y, Chen B, Wang JH, Li JM, Mi JQ, Chen QS, Zhu YM, Jiang CL, Yan H, Zhang XX, Huang T, Zhu Z, Chen Z, Chen SJ.

Blood Cancer J. 2013 Aug 16;3:e133. doi: 10.1038/bcj.2013.31.

2.

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.

Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H.

Cancer. 2017 Feb 1;123(3):426-435. doi: 10.1002/cncr.30361. Epub 2016 Sep 22.

PMID:
27657543
3.

[Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].

Xu XJ, Tang YM, Song H, Shi SW, Yang SL, Shen HQ, Wei J, Xu WQ, Pan BH, Zhao FY.

Zhonghua Er Ke Za Zhi. 2010 Mar;48(3):180-4. Chinese.

PMID:
20426951
4.

Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.

Huang YJ, Coustan-Smith E, Kao HW, Liu HC, Chen SH, Hsiao CC, Yang CP, Jaing TH, Yeh TC, Kuo MC, Lai CL, Chang CH, Campana D, Liang DC, Shih LY.

J Formos Med Assoc. 2017 Jan 4. pii: S0929-6646(16)30480-6. doi: 10.1016/j.jfma.2016.12.002. [Epub ahead of print]

5.

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, Burnett AK.

J Clin Oncol. 2013 Nov 10;31(32):4123-31. doi: 10.1200/JCO.2013.49.1753. Epub 2013 Sep 23.

PMID:
24062403
6.

Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.

Šálek C, Folber F, Froňková E, Procházka B, Marinov I, Cetkovský P, Mayer J, Doubek M; Czech Leukemia Study Group - for Life..

Eur J Haematol. 2016 Mar;96(3):276-84. doi: 10.1111/ejh.12587. Epub 2015 Jun 22.

PMID:
25997106
7.

[Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].

Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM.

Zhongguo Dang Dai Er Ke Za Zhi. 2008 Jun;10(3):333-6. Chinese.

PMID:
18554462
8.

Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.

Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M.

Int J Hematol. 2010 Oct;92(3):481-9. doi: 10.1007/s12185-010-0670-1. Epub 2010 Sep 10.

PMID:
20830615
9.

[Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].

Guo DD, Zhao WL, Zhang YL, Pang L, Che L, He HL, Chai YH, Ji ZH, Ji XQ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Dec;20(6):1346-51. Chinese.

PMID:
23257430
10.

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

Vidriales MB, Pérez JJ, López-Berges MC, Gutiérrez N, Ciudad J, Lucio P, Vazquez L, García-Sanz R, del Cañizo MC, Fernández-Calvo J, Ramos F, Rodríguez MJ, Calmuntia MJ, Porwith A, Orfao A, San-Miguel JF.

Blood. 2003 Jun 15;101(12):4695-700. Epub 2003 Feb 13.

11.

Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.

Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E.

J Clin Oncol. 2014 May 20;32(15):1595-604. doi: 10.1200/JCO.2013.52.2425. Epub 2014 Apr 21.

PMID:
24752047
12.

[A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].

Wang L, Zhang LP, Li ZG, Cheng YF, Tian KG, Lu AD.

Zhonghua Er Ke Za Zhi. 2005 Mar;43(3):170-3. Chinese.

PMID:
15833185
14.

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.

Zhao XS, Liu YR, Zhu HH, Xu LP, Liu DH, Liu KY, Huang XJ.

Ann Hematol. 2012 Feb;91(2):183-92. doi: 10.1007/s00277-011-1285-1. Epub 2011 Jun 28.

PMID:
21710165
15.

[Prognostic Significance of Joint Detection of miR-210 and Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia].

Mei YY, Li ZG, Zhang Y, Zhang WL, Zhang PW, Wang N, Huang DS.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):66-71. doi: 10.7534/j.issn.1009-2137.2017.01.011. Chinese.

PMID:
28245377
16.
17.

Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.

Malagola M, Skert C, Borlenghi E, Chiarini M, Cattaneo C, Morello E, Cancelli V, Cattina F, Cerqui E, Pagani C, Passi A, Ribolla R, Bernardi S, Giustini V, Lamorgese C, Ruggeri G, Imberti L, Caimi L, Russo D, Rossi G.

Cancer Med. 2016 Feb;5(2):265-74. doi: 10.1002/cam4.593. Epub 2015 Dec 29.

18.

[Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].

Liu YR, Zhang LP, Chang Y, Cheng YF, Fu JY, Li LD, Wang H, Liu GL, Chen SS, Huang XJ, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2006 May;27(5):302-5. Chinese.

PMID:
16875577
19.

[Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].

Cho YU, Park CJ, Cha CH, Chi HS, Jang S, Kim MJ, Lee KH, Lee JH, Lee JH, Seo JJ, Im HJ.

Korean J Lab Med. 2010 Dec;30(6):533-9. doi: 10.3343/kjlm.2010.30.6.533. Korean.

20.

Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.

Bastos-Oreiro M, Perez-Corral A, Martínez-Laperche C, Bento L, Pascual C, Kwon M, Balsalobre P, Muñoz C, Buces E, Serrano D, Gayoso J, Buño I, Anguita J, Diéz-Martín JL.

Eur J Haematol. 2014 Sep;93(3):239-46. doi: 10.1111/ejh.12336. Epub 2014 Apr 29.

PMID:
24702162

Supplemental Content

Support Center